PTH analogues and osteoporotic fractures (Q37772506)

22 August 2017

1 reference

title

PTH analogues and osteoporotic fractures (English)

1 reference

22 August 2017

0 references

Harald J J Verhaar

1

1 reference

22 August 2017

Willem F Lems

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

1387-1394

1 reference

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Hip fractures in the elderly: a world-wide projection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Epidemiology of osteoporosis and osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

The Amino-Acid Sequence of the Amino-Terminal 37 Residues of Human Parathyroid Hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Comment on Kanis et al.: "European guidance for the diagnosis and management of osteoporosis in postmenopausal women".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Reduced risk of back pain following teriparatide treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Persistence with teriparatide in patients with osteoporosis: the UK experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

Anabolic therapy in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.2010.506870

10.1517/14712598.2010.506870

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference